<DOC>
	<DOCNO>NCT00037115</DOCNO>
	<brief_summary>The participant receive weekly intramuscular treatment AVONEX® ( interferon beta 1-a ) one-time high dose intravenous methotrexate Leucovorin rescue , along standard solumedrol treatment begin AVONEX® treatment .</brief_summary>
	<brief_title>Induction Therapy With Single High Dose Bolus Intravenous Methotrexate With Leucovorin Rescue , Prior Initiation AVONEX® Treatment , Patients Presenting With First Acute Demyelinating Event .</brief_title>
	<detailed_description>The participant receive weekly intramuscular treatment AVONEX® ( interferon beta 1-a ) one-time high dose intravenous methotrexate Leucovorin rescue , along standard solumedrol treatment begin AVONEX® treatment . At study entrance , baseline lab work ( complete blood count , platelet count , routine electrolyte , blood urea nitrogen , creatinine , liver function test , 24 hour urine collection creatinine clearance , urine pregnancy test , urinalysis urine culture sensitivity need ) , electrocardiogram ( measurement heart activity ) do . A complete medical history , neurological opthamological examination perform , include measurement vital sign ( heart rate blood pressure ) , well magnetic resonance imaging ( MRI ) , EDSS , Visual Evoked Response test ( VER 's ) document status disease . A Multiple Sclerosis Functional Composite Score ( MSFC ) consist Timed 25 Foot Walk , Nine Hole Peg Test ( 9HPT ) , Paced Auditory Serial Addition Test 3 ( PASAT3 ) perform screen well . At month 6 , 12 , 18 , 24 , 30 36 test evaluation include MRI , MSFC , VER 's blood test immune cell . Other safety evaluation ( previously mention blood urine test ) conduct accord date treatment . These test include laboratory test ( methotrexate level ) two day follow treatment , well routine lab test 2 week follow methotrexate treatment . This treatment would supervision Dr. Rowe . The patient continue AVONEX® intramuscular injection 30 microgram ( administer patient caregiver ) weekly basis . The methylprednisolone treatment methotrexate infusion perform outpatient infusion center . The patient require complete patient diary course trial , participate keep scheduled appointment , inform research staff physician change concomitant medication adverse event may experience .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Myelitis</mesh_term>
	<mesh_term>Demyelinating Diseases</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>To eligible entry study , candidate must meet following eligibility criterion time enrollment , CHAMPS study [ 1 ] : Between age 18 50 year , inclusive . As CHAMPS study [ 1 ] patient must first isolate , welldefined neurologic event consistent demyelination involve optic nerve ( unilateral optic neuritis ) , spinal cord ( incomplete transverse myelitis ) , brain stem cerebellum ( brain stem cerebella syndrome ) . They must also two clinically silent lesion brain least 3 mm diameter MRI scan characteristic MS ( least one lesion must periventricular ovoid ) . The onset visual neurological symptom must occur twelve day MTX treatment , methylprednisolone treatment begin fourteen day onset symptom , CHAMPS . Patients must give write informed consent prior test protocol , include screen test evaluation consider part subject 's routine care .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Demyelinating</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Myelitis</keyword>
	<keyword>Neuritis</keyword>
	<keyword>Optic Neuritis</keyword>
	<keyword>AVONEX</keyword>
	<keyword>methotrexate</keyword>
	<keyword>methylprednisolone</keyword>
	<keyword>interferon beta 1a</keyword>
	<keyword>demyelination</keyword>
	<keyword>central nervous system</keyword>
	<keyword>brain</keyword>
	<keyword>nerve</keyword>
	<keyword>lesion</keyword>
	<keyword>enhancement</keyword>
	<keyword>enhance</keyword>
</DOC>